Unaudited Standalone & Consolidated Financial Results of the company for the quarter ended 30th June, 2026.

GENPHARMASEC LIMITED Date: 11.08.2026 BSE Limited The Compliance Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 531592 Subject: Outcome of the Meeting of Board of Directors held on Tuesday, 11t August, 2026. Dear Sir/ Madam, With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held on today, ie. Tuesday, 11t August, 2026, inter alia, considered and approved: 1. The Un-audited Standalone & Consolidated Financial Results of the Company for the quarter ended 30t June, 2026 along with Limited Review Report after these results are reviewed by the Audit Committee. We further inform you that the Board Meeting commenced at 03:00 p.m. today and concluded at 03:50 p.m. Kindly take the same on records for your perusal. Thanking you, Yours faithfully, For and behalf of the Board of Director of, Genpharmasec Limited SOHAN sc imrinvio CHATURVED| Date2mzscs i 1515225 +0530 Mr. Sohan Chaturvedi Whole time director & CFO DIN- 09629728 Encl: 1. Un-Audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. 2. Limited Review Reports. 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc compliance@genpharmasec.com Ltd., Akurli Road, Kandivali (East), Mumbai 400101. info@genpharmasec.com () +91-86555 50242 @ www.genpharmasec.com CIN : L24231MH1992PLC323914 BILIMORIA MEHTA & CO. CHARTERED ACCOUNTANTS Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Genpharmasec Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Genpharmasec Limited ('the Company"') for the quarter ended June 30, 2026 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. 2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Mumbai : Corporate Office: 507/508, 5th Floor, INIZIO, Cardinal Gracious Road, Chakala, Andheri (East), Mumbai- 400 099, Tel : +01 22 6697 2111/12/13, 2837 5622/33 Registered Office : Sethna Buildging, 15t Floor, 216, Shamaldas Gandhi Ma( Prrincgess Street), Mumb-a 4i00 002. Tel : +91-22-2201 4834/6807 New Delhi : 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi - 110 001. Tel - +91-11-43543750/23736049 Kolkata : Ground Floor, Jyotermoyee Buildging, 2712, Chakrabaria Lane, Kolkata - 700 020 (West Bengal) Tel : +91-9804879857 Website : www.bilimoriamenta.in e Email : admin@bilimoriamehta.com BILIMORIA MEHTA & CO. CHARTERED ACCOUNTANTS 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. The review of standalone unaudited financial results for the period ended June 30, 2025, included in the Statement was carried out and reported by Abhishek S Tiwari & Associates who have expressed unmodified conclusion vide their review report dated August 07, 2025 whose review reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter. For Bilimoria Mehta & Co. Chartered Accountants FRN: 101490W Aosmate Aakash Mehta Partner Membership no. 165824 UDIN: 26165824QYEYUH3366 Place of Signature: Mumbai Date: August 11, 2026 Mumbai : Corporate Office: 507/508, 5th Floor, INIZIO, Cardinal Gracious Road, Chakala, Andheri (East), Mumbai - 400 099, Tel : +91 22 6697 2111/12/13, 2837 5522133 Registered Office : Sethna Buildging, 15t Floor, 216, Shamaldas Gandhi Marg ( Princess Street), Mumbai - 400 002. Tel : +91-22-2201 4834/6807 New Delhi : 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi - 110 001. Tel - +91-11-43543750/23736049 Kolkata : Ground Floor, Jyotermoyee Buildging, 2712, Chakrabaria Lane, Kolkata - 700 020 (West Bengal) Tel : +91-9804879857 Website : www.bilimoriamenta.in e Email : admin@bilimoriamehta.com GENPHARMASEC LIMITED Corporate Identity Number (CIN): L24231MH1992PLC323914 Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30,2026 (All amounts are in INR Lakhs, unless otherwise stated) Quarter ended | Quarter ended | Quarter ended | For the year ended ":'3 Particulars June 30,2026 | March31,2026 | June30,202§ | March 31,2026 et (Unaudited) | (Audited) (Unoudited) (Audited) T | Revenue from operations 44744 516642 121132 1313404 11 Other Income 97.06 16179 8224 48694 I | Total Income @+ T 457550 552822 139355 T3,621.88 IV | Expenses Purchase of Stock-in-Trade 453097 465489 112256 313994 Changes in Inventories of Finished goods and Stock-in-Trade (249.09) 24920 (69.89)] (53338) Employee henefit expense 2421 2462 2119 0727 Finance Costs 1270 2475 767 936 Depreciation and Amortization Expense 977 9.42 431 2560 Other Expenses 3719 .07 3707 18939 Total Expenses (IV) 36578 504193 112297 1297819 V| Profit before tax (-I IV) 209.72 28627 17058 643.69 VI | Tax expense: (1) Current tax 5166 6280 1681 15232 (2) Deferred Tax 110 (3.34) (215) a773) (3) Prior Period Tax 3 : - (35.56)] Total Tax Expense £33 X 1166 7T VIT | Profit for the period (V-VI) 5696 EEIE] 15552 w56 VIIT | Other Comprehensive Income/(Loss) (i) Items that will not be reclassified to Profit and Loss (a) Remeasurement of post employment defined benefit plans 2 e 052 (b) Incom [Showing first 8,000 characters — download PDF for full document]